Therapeutic potential of azithromycin in rosacea

International Journal of Dermatology

Volumn 43, Issue 2, 2004, Pages 151-154

  Bakar, Özgür ^a,b   Demirçay, Zeynep ^a   Gürbüz, Oya ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AZITHROMYCIN; COPPERTONE; MACROLIDE;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; OPEN STUDY; PATIENT COMPLIANCE; POPULATION RESEARCH; ROSACEA; SCORING SYSTEM; SIDE EFFECT; SKIN DEFECT; SKIN INFLAMMATION; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AZITHROMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SATISFACTION; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; ROSACEA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 1342290370     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2004.01958.x     Document Type: Article

References (14)

1. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: Report of the national rosacea society expert committee on the classification and staging of rosacea. J Am Acad Dermatol 2002; 46: 584-587.
2. Plewig G, Jansen T. Rosacea. In: Freedberg IM, Eisen AZ, Wolff K, et al., eds. Fitzpatrick's Dermatology in General Medicine, 5th ednEDZ, Vol. 1. New York: McGraw-Hill, 1999: 785-794.
3. Del Rosso JQ. Systemic therapy for rosacea: Focus on oral antibiotic therapy and safety. Cutis 2000; 66: 7-15.
4. Alvarez-Elcoro S, Enzler MJ. The macrolides: Erythromycin, Clarithromycin, Azithromycin. Mayo Clin Proc 1999; 74: 613-634.
5. Fernandez-Obregon A. Azithromycin for the treatment of acne. Int J Dermatol 2000; 39: 45-50.
6. Hendreson CA, Charles-Holmes S, McSween R, et al. A system for grading rosacea severity. Br J Dematol 1995; 133: 34.
7. Humbert P, Treffel P, Chapuis JF, et al. The tetracyclines in dermatology. J Am Acad Dermatol 1991; 25: 691-697.
8. Bannatyne RM. Metronidazole, its bioactive metabolites and acne. Curr Med Res Opin 1999; 15: 298-299.
9. Labro MT. Anti-inflammatory activity of macrolides: a new therapeutic potential? J Antimicrob Chemother 1998; 418: 37-46.
10. McDonald PJ, Pruul H. Phagocyte uptake and transport of azithromycin. Eur J Clin Microbiol Infect Dis 1991; 10: 828-833.
11. Scaglione F, Rossoni G. Comparative anti-inflammatory effects of roxithromycine, azithromycin and clarithromycin. J Antimicrob Chemother 1998; 411: 47-50.
12. Ianaro A, Ialenti A, Maffia P et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000; 292: 156-163.
13. Torresani C. Clarithromycin: a new perspective in rosacea treatment. Int J Dermatol 1998; 37: 343-349.
14. Williams JD, Sefton AM. Comparison of macrolide antibiotics. J Antimicrob Chemother 1993; 31: 11-26.